APHP - Hôpital Necker   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Paris France (1778)

Organization Overview

First Clinical Trial
2006
NCT02637726
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

APHP - Hôpital Necker | APHP Necker | AP-HP - Service médecine interne | Centre de référence maladies auto-immunes et systémiques rares, Internal medicine, Cochin hospital, APHP | Département de Biothérapie : Hôpital Necker Enfants malades | Department of Biotherapy,LTCG, Necker-Enfants Malades Hospital | Hôpital Lariboisière, Paris (AP-HP) | Hôpital Necker | Hôpital Pitié Salpêtrière - Assitance Publique Hôpitaux de Paris | Hôpital Pitié-Salpêtrière - Assitance Publique - Hôpitaux de Paris | Hospital Necker, Department of haematology and immunology | Hospital Necker Enfants Malades | Medical Intensive Care Unit, Ambroise Paré Hospital, APHP | Medical Intensive Care Unit, Cochin Hospital, APHP | Pr Isabelle CONSTANT | Virology laboratory- reference national Lab for CMV infection -Hôpital Necker-Enfants malades, Paris

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 2)

Coronavirus Infections (Phase 2)

Hemorrhage (Phase 3)

Immunoblastic Lymphadenopathy (Phase 3)

Lymphoma (Phase 3)

Lymphoma, T-Cell (Phase 3)

Lymphoma, T-Cell, Peripheral (Phase 2)

Mastocytosis (Phase 3)

Mastocytosis, Systemic (Phase 3)

Osteoporosis (Phase 3)

Pulmonary Alveolar Proteinosis (Phase 2)

Respiratory Distress Syndrome (Phase 2)

Respiratory Distress Syndrome, Newborn (Phase 2)

Severe Acute Respiratory Syndrome (Phase 2)

Subarachnoid Hemorrhage (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 18
  • # of Trial APIs: 32